Tg Therapeutics (TGTX) Change in Receivables (2021 - 2026)

Tg Therapeutics' Change in Receivables history runs 6 years deep, the most recent figure standing at $86.4 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 41.82% year-over-year to $86.4 million; the TTM figure through Mar 2026 stood at $201.9 million (up 61.36% YoY), while the FY2025 annual figure was $176.4 million, up 125.94% from the prior year.
• Change in Receivables for Q1 2026 stood at $86.4 million, up from $40.2 million in the prior quarter.
• The five-year high for Change in Receivables was $86.4 million in Q1 2026, with the low at -$814000.0 in Q2 2022.
• The 5-year median for Change in Receivables is $16.3 million (2024), against an average of $24.4 million.
• The sharpest annual moves came in 2022 and 2023: Change in Receivables slumped 608.75% in 2022, then surged 24913.64% in 2023.
• Tg Therapeutics' Change in Receivables stood at -$88000.0 in 2022, then jumped by 13478.41% to $11.8 million in 2023, then advanced by 14.31% to $13.5 million in 2024, then surged by 199.03% to $40.2 million in 2025, then soared by 114.74% to $86.4 million in 2026.
• Business Quant data shows TGTX's Change in Receivables at $86.4 million in Q1 2026, $40.2 million in Q4 2025, and $33.9 million in Q3 2025.